<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781480</url>
  </required_header>
  <id_info>
    <org_study_id>MGT003</org_study_id>
    <nct_id>NCT02781480</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)</brief_title>
  <acronym>OPTIRPE65</acronym>
  <official_title>An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of AAV2/5 vector for patients with Defects in RPE65
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose escalation and dose expansion (Phase I/II) trial of adults and children with retinal
      dystrophy associated with defects in RPE65. ATIMP will be administered to one eye only in a
      single sub-retinal procedure
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>AAV2/5-OPTIRPE65</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events related to the treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Safety is defined as the absence of ATIMP-related safety events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in visual function</measure>
    <time_frame>6 months</time_frame>
    <description>Improvements in visual function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in retinal function</measure>
    <time_frame>6 months</time_frame>
    <description>Improvements in retinal function as assessed by visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life will be measured by QoL questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Leber Congenital Amaurosis</condition>
  <arm_group>
    <arm_group_label>Low dose AAV-RPE65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single low dose of range AAV-RPE65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose AAV-RPE65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single intermediate dose of range AAV-RPE65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose AAV-RPE65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subretinal administration of a single high dose of range AAV-RPE65</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV RPE65</intervention_name>
    <description>Comparison of different dosages of AAV RPE65</description>
    <arm_group_label>High dose AAV-RPE65</arm_group_label>
    <arm_group_label>Intermediate dose AAV-RPE65</arm_group_label>
    <arm_group_label>Low dose AAV-RPE65</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Aged 3 years or older

          -  Early-onset severe retinal dystrophy consistent with RPE65 deficiency

        Key Exclusion Criteria:

          -  Females who are pregnant or breastfeeding

          -  Have participated in another research study involving an investigational therapy for
             ocular disease within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kellogg Eye Centre, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

